Bajaj Healthcare Limited has submitted its Monitoring Agency Report for the quarter ended December 31, 2025. The report, issued by CARE Ratings Limited, confirms that there have been no deviations from the stated objects for the utilization of proceeds from the Preferential Issue of Equity Shares and Convertible Warrants.

The total issue size was Rs. 204.97 crore. The funds were earmarked for repayment of loans (Rs. 150.00 crore), capital expenditure (Rs. 35.00 crore), and general corporate purposes (Rs. 19.97 crore). For the quarter ending December 31, 2025, there was nil utilization of funds.

As of December 31, 2025, a total of Rs. 152.25 crore has been utilized, primarily for the repayment of secured/unsecured loans. The remaining unutilized amount is Rs. 52.72 crore, which represents the uncalled portion of the convertible warrants. The company expects to receive this amount within 18 months from the allotment date, September 19, 2024.

The definition of General Corporate Purpose was revised on November 14, 2024, to include the repayment of unsecured loans taken for working capital requirements, following board and audit committee approvals. This revision was made to accommodate a Rs. 2.25 crore allocation towards promoter unsecured loan repayment in Q2FY25.